OncoMatch/Clinical Trials/NCT06791681
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Is NCT06791681 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies ESO-T01 for relapsed/ refractory multiple myeloma.
Treatment: ESO-T01 — This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) expression (expression on MM cells by flow cytometry or immunohistochemistry)
BCMA expression on MM cells determined by flow cytometry or immunohistochemistry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-myeloma therapy
Previously treated with at least 2 lines of anti-MM therapy, with at least 1 complete treatment cycle for each line, and disease progression within 12 months after the most recent anti-myeloma treatment
Cannot have received: targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices
Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices within 5 half-lives
Cannot have received: immune/non-immune-directed systemic therapy
Received immune/non-immune-directed systemic therapy within 1 week
Cannot have received: cytotoxic therapy
Received cytotoxic therapy within 1 week
Cannot have received: proteasome inhibitor
Received proteasome inhibitors or immunomodulatory agent therapy within 2 weeks
Cannot have received: immunomodulatory drug
Received proteasome inhibitors or immunomodulatory agent therapy within 2 weeks
Cannot have received: radiation therapy
Exception: if the radiation field covered ≤5% of bone marrow reserve, the subject is eligible regardless of the date of radiotherapy completion
Received radiotherapy within 4 weeks (if the radiation field covered ≤5% of bone marrow reserve, the subject is eligible regardless of the date of radiotherapy completion)
Cannot have received: allogeneic hematopoietic stem cell transplant
Received allogeneic HSCT within 6 months prior to infusion
Cannot have received: autologous hematopoietic stem cell transplant
autologous HSCT within 3 months prior to infusion
Cannot have received: viral therapy using VSVG pseudotype virus
Previously treated with any viral therapy using VSVG pseudotype virus
Lab requirements
Blood counts
Hemoglobin ≥ 6 g/dL (no red blood cell transfusion within 1 week before screening, recombinant human erythropoietin allowed); ANC ≥ 600/μL (no G-CSF within 1 week or pegylated G-CSF within 2 weeks prior to screening); Platelet count ≥ 50,000/μL; Lymphocyte count ≥ 500/μL; Absolute CD3-positive T cell count ≥ 150/μL
Kidney function
creatinine clearance ≥ 45 mL/min
Liver function
ALT and AST ≤ 3.0 × ULN; TBIL and ALP ≤ 2.0 × ULN (except for congenital hyperbilirubinemia, such as Gilbert's syndrome, where direct bilirubin can be ≤ 1.5 × ULN); Albumin ≥ 3 g/dL
Cardiac function
Left ventricular ejection fraction ≥ 40% (measured by echocardiogram or MUGA scan); No clinically significant pericardial effusion detected; No clinically significant ECG abnormalities detected
Bone marrow function at screening (or within 2 months prior to screening) meets the following criteria: ... Renal function at screening (or within 2 months prior to screening) should be normal, with a creatinine clearance ≥ 45 mL/min; Liver function at screening (or within 2 months prior to screening) must meet the following criteria: ... Cardiac function at screening (or within 2 months prior to screening) must meet the following criteria: ...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06791681 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices, immune/non-immune-directed systemic therapy, cytotoxic therapy disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages